Company: INDP
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001641172-25-005234
Chunk: 23

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 23
---
 executive officer, but rather the overall compensation of all of our named executive officers and the philosophy, policies and practices described in this proxy statement. We currently have a policy providing for a triennial vote on our Executive Compensation Proposal. The Board of Directors recommends that stockholders approve an advisory resolution in favor of the Executive Compensation Proposal. We anticipate that the next advisory vote on the compensation of our named executive officers would occur in 2028. The vote is advisory, and therefore not binding on the Company, the compensation committee or the Board of Directors. The voting outcome will, however, provide information to us regarding investor sentiment about our executive compensation philosophy, policies and practices, which the compensation committee will be able to consider when determining executive compensation for the remainder of the current fiscal year and beyond. The Board of Directors and the compensation committee value the opinions of our stockholders and to the extent there is any significant vote against our named executive officer compensation as disclosed in this proxy statement, we will consider our stockholders’ concerns and the compensation committee will evaluate whether any actions are necessary to address those concerns.

Details of the Executive Compensation Proposal

For further details on the Executive
Compensation currently, please refer to the section “Executive Compensation” on page 27 of this proxy statement.

| 13 |

Vote Required

This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. Abstentions are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. This is a non-binding advisory vote.

Recommendation of the Board of Directors

The Board of Directors unanimously recommends a vote FOR the approval of the executive compensation of the executive officers named herein.

PROPOSAL 4: REVERSE STOCK SPLIT

Overview

Our Board of Directors deems it advisable and in the best interest of the Company that the Board of Directors be granted the discretionary authority to amend the Company’s Restated Certificate to effect the Reverse Stock Split of the Company’s issued and outstanding common stock as described below (the “Reverse Stock Split Amendment”).

The form of Reverse Stock Split Amendment to be filed with the Delaware Secretary of State is set forth in Appendix A.

Approval of the proposal would permit (but not require) our Board of Directors to effect one or more reverse stock splits of our issued and outstanding common stock by a ratio of not less than 1-for-5 and not more than 1-for-28, with the exact ratio to be set at a number within